Scarica l'app Stockscreener
1.03
1.98%
0.02
Dopo l'orario di chiusura:
1.01
-0.02
-1.94%
Precedente Chiudi:
$1.01
Aprire:
$0.96
Volume 24 ore:
308.70K
Relative Volume:
0.17
Capitalizzazione di mercato:
$176.80M
Reddito:
-
Utile/perdita netta:
$52.50M
Rapporto P/E:
35.40
EPS:
0.0291
Flusso di cassa netto:
$-4.13M
1 W Prestazione:
-4.63%
1M Prestazione:
-9.65%
6M Prestazione:
+222.38%
1 anno Prestazione:
-64.73%
Intervallo 1D:
$0.9311
$1.05
Intervallo di 1 settimana:
$0.89
$1.12
Portata 52W:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Nome
Tevogen Bio Holdings Inc
Settore
Industria
Telefono
646-807-8832
Indirizzo
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Confronta TVGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.03 | 176.80M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Iniziato | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Borsa (TVGN) Ultime notizie
Tevogen reports high insider ownership amid market volatility - Investing.com India
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission - The Manila Times
Tevogen Bio Holdings Inc. SEC 10-K Report - TradingView
Tevogen Bio Holdings Delays Annual Report Filing - TipRanks
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - The Manila Times
Thomas Butler steps down as Biomea CEO - BioCentury
Tevogen Bio's Ambitious $2B Revenue Target Backed by Leadership Excellence and Key Hire - Stock Titan
Tevogen Bio appoints new head of government affairs By Investing.com - Investing.com South Africa
Tevogen Bio appoints new head of government affairs - Investing.com
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Quantisnow
Tevogen Bio Appoints David E. Banko as Global Head of - GlobeNewswire
TSX Continues Higher as U.S. Trade Policy Appears to Soften - The Globe and Mail
SPY ETF News, 3/21/2025 - The Globe and Mail
Meta Stock Dips Below $600: A Buying Opportunity or a Red Flag? - The Globe and Mail
Tevogen Bio CEO reinforces commitment to retention of equity capital - MSN
Tevogen Bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen bio’s chief scientific officer sells $253,935 in stock By Investing.com - Investing.com Australia
Tevogen Bio’s chief scientific officer sells $253,935 in stock - Investing.com India
Tevogen bio’s chief scientific officer sells $253,935 in stock - Investing.com
Tevogen Bio Holdings Officer Sells Shares to Cover Tax Obligations - TradingView
Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Short Interest Down 86.7% in February - Defense World
Tevogen Bio (NASDAQ:TVGN) Receives “Buy” Rating from D. Boral Capital - Defense World
Public market insider selling at Aura Minerals (ORA) - The Globe and Mail
Tevogen bio’s chief scientific officer sells shares worth $231,734 By Investing.com - Investing.com South Africa
Tevogen bio’s chief scientific officer sells shares worth $231,734 - Investing.com India
Tevogen Bio Files New US Patent for T Cell Vaccine Under Development -March 10, 2025 at 01:19 pm EDT - Marketscreener.com
Tevogen announces new patent filed for T cell vaccine - TipRanks
Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO - Marketscreener.com
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - The Manila Times
Tevogen Bio Files Patent for Innovative T Cell Vaccine Targeting Entire Viral Genome to Combat Mutations - Nasdaq
Tevogen Bio Files Patent for AI-Powered T Cell Vaccine with Military Applications - StockTitan
Have Tevogen Bio Holdings Insiders Been Selling Stock? - simplywall.st
Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft - Insider Monkey
Tevogen bio’s chief scientific officer sells shares totaling $250k By Investing.com - Investing.com South Africa
Tevogen Bio's CIO Mittul Mehta Discusses AI Innovations in Biotech at Proskauer Panel - Nasdaq
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel - GlobeNewswire
Can AI Transform Biotech? Tevogen's Tech Chief Reveals Next-Gen Strategy - StockTitan
Tevogen Bio’S CIO & Head Of Tevogen.AI, Mittul Mehta, Featured Speaker At Proskauer’S AI Discussion Panel - MENAFN.COM
Tevogen bio’s chief scientific officer sells shares totaling $250k - Investing.com
9 AI News Updates Investors Should Not Miss - Insider Monkey
D. Boral Capital Begins Coverage on Tevogen Bio (NASDAQ:TVGN) - Defense World
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential - Benzinga
This Tevogen Bio Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga India
Tevogen initiated with a Buy at D. Boral Capital - TipRanks
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - GlobeNewswire
Tevogen Bio To Receive $8 Mln Of Non-Dilutive Grant Funding - MarketScreener
Tevogen Bio Secures Additional $8 Million Grant from KRHP LLC to Advance AI-Driven Immunotherapy Developments - Nasdaq
Tevogen Bio Holdings Inc Azioni (TVGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tevogen Bio Holdings Inc Azioni (TVGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Flomenberg Neal | See Remarks |
Mar 07 '25 |
Sale |
1.14 |
71,273 |
81,251 |
3,969,212 |
| Flomenberg Neal | See Remarks |
Mar 10 '25 |
Sale |
1.09 |
70,384 |
76,719 |
3,898,828 |
| Flomenberg Neal | See Remarks |
Mar 11 '25 |
Sale |
1.05 |
70,252 |
73,765 |
3,828,576 |
| Flomenberg Neal | See Remarks |
Mar 05 '25 |
Sale |
1.21 |
110,659 |
133,897 |
4,129,004 |
| Flomenberg Neal | See Remarks |
Mar 06 '25 |
Sale |
1.10 |
88,519 |
97,371 |
4,040,485 |
| Flomenberg Neal | See Remarks |
Mar 04 '25 |
Sale |
1.28 |
14,639 |
18,738 |
4,239,663 |
| Flomenberg Neal | See Remarks |
Oct 17 '24 |
Sale |
1.62 |
1,078,600 |
1,747,332 |
4,254,302 |
| Desai Kirti | Chief Financial Officer |
Jun 12 '24 |
Buy |
0.82 |
3,000 |
2,460 |
9,699,186 |
| Saadi Ryan H. | Chief Executive Officer |
Jun 05 '24 |
Buy |
0.77 |
2,607 |
2,000 |
118,252,659 |
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):